miRNAs in stem cell-derived extracellular vesicles for acute kidney injury treatment: comprehensive review of preclinical studies

Si-Yang Wang, Quan Hong, Chao-Yang Zhang, Yuan-Jun Yang, Guang-Yan Cai* and Xiang-Mei Chen

Abstract

Stem cell therapy has been applied in many fields. Basic and clinical studies on stem cell therapy for acute kidney injury (AKI) have been conducted. Stem cells have been found to exert renal protection through a variety of mechanisms, such as regulating the immune system and secreting growth factors, cytokines, and extracellular vesicles (EVs). Among them, EVs are considered to be important mediators for stem cell protection because they contain various biological components, including microRNAs (miRNAs). miRNAs are a class of small RNAs that function in posttranscriptional gene regulation. A number of studies have confirmed that miRNAs in stem cell-derived EVs can protect from AKI. miRNAs can enter the injured renal tissue through EVs released from stem cells, thereby exerting anti-inflammatory, anti-apoptotic, anti-fibrotic, and pro-angiogenesis effects on AKI. However, the stem cell sources and AKI models used in these studies have differed. This article will summarize the miRNAs that play a role in kidney protection in stem cell EVs and clarifies the treatment characteristics and mechanisms of different miRNAs. This may provide a reference for clinical practice for acute and chronic kidney diseases.

Keywords: Stem cell, microRNA, Acute kidney injury

Background

Extracellular vesicles (EVs) are membrane-enclosed microvesicles released by cells. EVs carry various biological molecules, including microRNAs (miRNAs), proteins, mRNAs, long noncoding RNAs, DNA, and lipids, and deliver them to recipient cells [1]. EVs were first thought to be a mechanism for cells to remove metabolic waste and maintain cellular homeostasis. Later, they were found to play a key role in cell communication. It is currently believed that EVs are an important route for cellular communication and can be released and endocytosed by most types of cells [2].

The miRNAs in EVs are important regulators of intercellular communication. miRNAs, which are widely present in eukaryotes, are a class of noncoding, single-stranded, small-molecule RNAs approximately 18–25 nucleotides in length. They can inhibit target mRNA translation or induce target mRNA degradation through partial or full complementarity to the 3′ untranslated region of target mRNAs, thereby enabling posttranscriptional gene regulation [3]. Stem cells have been shown to play a therapeutic role in acute kidney injury (AKI) by secreting EVs rich in miRNAs, and the mechanism has been extensively studied. The protective effect of EVs on kidney injury can be reversed by miRNA deficiency caused by knocking out the ribonuclease III Drosha gene in mesenchymal stem cells (MSCs) [4]. However, stem cells from different sources may have different miRNAs that function in different types of AKI. This study will summarize the miRNAs in stem cell-derived EVs with confirmed therapeutic effects on AKI.

Stem cell-derived EVs and miRNAs

Almost all cell types in the human body can secrete EVs that subsequently enter circulation. EVs transmit signals to distant cells via paracrine mechanisms to mediate intercellular communication and participate in a variety of physiological and pathological processes. Therefore, EVs are considered important information carriers that regulate the gene expression and phenotypes of adjacent or distal recipient cells through paracrine mechanisms [5].

EVs can mediate the communication between stem cells and damaged cells. On the one hand, EVs secreted by stem cells can act on damaged cells. For example,
EVs secreted by mouse embryonic stem cells can reprogram hematopoietic progenitor cells by transmitting transcription factors, proteins, and mRNAs [6]. On the other hand, studies have shown that damaged cells can secrete EVs to regulate stem cell functions [7]. EVs derived from injured cells can transmit specific signals to stem cells and trigger stem cell differentiation, which may be another potential mechanism for EVs to repair pathological tissues [8].

Paracrine mechanisms are one of the important modes through which stem cells play a therapeutic role in AKI. The therapeutic effect of EVs on AKI has been extensively studied (Fig. 1). Many studies have demonstrated the therapeutic effect of EV injection alone on AKI. Various substances contained in EVs—such as angiogenin, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), proteins that regulate apoptosis (caspase-14) and inflammation (IL-10), and mRNA involved in regulating transcription, cell cycle, and the immune system [9]—can play a protective role in the kidney. Recent studies have shown that miRNAs may also be important mediators of stem cell EVs for organ protection [10]. Alex et al. confirmed for the first time that EVs derived from embryonic stem cells can deliver miRNA to target cells [11]. Since then, in-depth studies have been conducted on the role of stem cell EV miRNAs in target organs. In 2011, Gatti et al. used high concentrations of RNase to pretreat human bone marrow-derived MSCs to inhibit RNA activity and found that the protective effect of MSC EVs on ischemia/reperfusion-induced acute/chronic renal injury in rats was significantly weakened, apoptosis was increased, and proliferation was reduced. These results indicate that miRNAs carried by stem cells derived from EVs play an important role in alleviating renal damage in rats [12]. miRNAs have gradually opened a new direction in the study of protective mechanisms of stem cell EVs in the kidney (Table 1).

**miRNAs play important roles in the pathological changes resulting from AKI**

Through posttranscriptional gene regulation, miRNAs play important roles in kidney development and physiological conditions as well as pathological conditions. For example, miRNAs are involved in diabetic nephropathy, polycystic kidney disease, hypertensive nephropathy, chronic kidney disease (CKD), and kidney transplantation [13]. In 2016, Dong et al. summarized the miRNAs...
involved in AKI pathology. Among the two widely used AKI models, kidney ischemia injury and cisplatin-induced toxic injury, at least a dozen miRNAs regulate major pathways involved in inflammation, apoptosis, fibrosis, and the cell cycle, such as phosphatase and tensin homolog (PTEN), heme oxygenase (HO-1), phosphoinositide 3-kinases (PI3K), forkhead box O3 (Foxo3), B cell lymphoma 2 (BCL-2), and hypoxia-inducible factor (HIF)-1, indicating the important role of miRNAs in AKI [14]. In 2018, studies on related topics continued to be published, confirming that cisplatin-induced upregulation of miRNA-709 in an AKI model and inhibition of mitochondrial transcription factor A (TFAM) lead to mitochondrial dysfunction and renal tubular apoptosis. The increased miRNA-709 has also been detected in kidney tissue of patients with AKI with multiple etiologies [15]. These results all indicate the important role of miRNAs in the AKI pathological process.

Almeida et al. performed miRNA microarray detection, gene ontology (GO) analysis, and target gene prediction in kidney tissue with cisplatin-induced AKI and stem cell therapy. They found that the treatment with stem cells involved a substantial miRNA-mRNA regulatory network. For example, miRNA-294, miRNA-141, and miRNA-588 are associated with the Wnt/TGF-β pathways. The authors also speculated that these miRNA changes might be associated with EVs secreted by stem cells [16].

### Table 1: The study of miRNA in stem cell EVs for AKI

| Study            | Animal Model | Stem cell source | Route of administration | Method/miRNA | Result                                                                 |
|------------------|--------------|------------------|-------------------------|--------------|----------------------------------------------------------------------|
| Gatti et al. 2011 [12] | Rat IRI | Human bone marrow | IV | Pretreatment of MVs with RNase | miRNA | Reduce TECs apoptosis and increase TECs proliferation |
| Collino et al. 2015 [4] | Rat Glycerol | Human bone marrow | IV | RNA-Seq, Drosha-Knockdown MSCs | miRNA | Anti-inflammation |
| Wang et al. 2016 [28] | Mouse UUO | Human bone marrow | IV | Engineered to overexpress miRNA-let-7c | miRNA | Alleviate kidney fibrosis |
| Wang et al. 2015 [19] | Mouse UUO | Mice primary bone marrow | IV | MicroRNA profiling arrays | miRNA | Enhanced inhibition of EMT |
| Wang et al. 2015 [19] | HK-2 TGF-β1-mediated | Rat bone marrow | IV | miRCURY LNA Array miRNA treatment | miR-133b-3p, miR-294 | Inhibited TGF-β1-mediated EMT |
| Yuan et al. 2017 [34] | Mouse IRI | Mice bone marrow | IV | miR-223 knockdown | miR-223 | Downregulation of NLKP3, suppressed apoptosis |
| Zhu et al. 2019 [36] | Mouse IRI | Human bone marrow | IV | Overexpression or knockdown of miR-199a-3p | miR-199a-3p | Restore Sema3A expression and block activation of the AKT and ERK pathways, antipoptosis |
| Zou et al. 2014 | Rat IRI | Human umbilical cord | IV | CX3CL1 in the TargetScan database, PCR | miR-15a, miR-15b and miR-16 | Cell proliferation, Antifibrosis |
| Gu et al. 2016 [43] | Rat IRI | Human umbilical cord | IV | miR-30 antagonist treat MSC | miR30 | Antiapoptosis, Preserved mitochondrial, morphology |
| Cantaluppi et al. 2012 | Rat IRI | Endothelial progenitor cells EPC | IV | miRNA array, anti-miR126 and anti-miR-296 antagoniRs | miR-126 and miR-296 | Enhancement of cell proliferation, Decrease in tubular cell apoptosis and leukocyte infiltration |
| Vinas et al. 2016 [51] | Rat IRI | Human cord blood endothelial colonyforming cells | IV | Trueq Small RNA kit antagoniR to miR-486-5p | miR-486-5p | Target at PTEN/Akt pathway |
| Pang et al. 2017 [52] | Rat IRI | Human renal artery-derived vascular progenitor cells | IV | miRNA microarray LNA-miR218 | miR-218 | Enhance endothelial cell migration |

**UUO** unilateral ureteral obstruction, **IRI** ischemia-reperfusion injury, **IV** intravenous, **TEC** tubular epithelial cells, **EMT** epithelial-mesenchymal transition

**Protective effect of MSC EV-derived miRNAs on AKI**

MSCs are pluripotent stem cells with high self-renewal ability and multidirectional differentiation potential. MSCs have been used to treat myocardial injury and nerve damage diseases in clinical practice. MSCs have been proven to play a therapeutic role in AKI and CKD models. Due to their homing effect, MSCs rarely accumulate in the kidney; therefore, paracrine action may be one of the important mechanisms through which MSCs alleviate kidney diseases. In addition to the release of cytokines, chemokines, and growth factors, paracrine effect
is closely associated with the abundant EVs that are secreted by MSCs [17].

In an in vitro model of ATP depletion-induced renal tubular cell injury, Rafael et al. found EV-mediated miRNA delivery from MSCs to renal tubular epithelial cells [18]. Subsequently, they used a glycerol-induced AKI rat model to further clarify the role of EV miRNAs. The double-stranded RNA-specific ribonuclease Drosha is an important enzyme in miRNA synthesis. In the nucleus, RNA molecules generated by the transcription are cleaved by Drosha into precursor miRNAs (pre-miRNAs). Using MSCs with Drosha knockdown, approximately 50 miRNAs in EVs secreted by MSCs were identified as significantly downregulated. Compared with normal MSC and EV treatments, the protective effects of genetically modified MSC-Dsh and EV-Dsh on AKI rats were reduced, as was renal tubular regeneration ability [4]. In the same year, Wang et al. pretreated MSC EVs with erythropoietin (EPO) and found that EPO treatment not only increased the number of EVs secreted from MSC but also significantly improved the inhibitory effect of EVs on fibrosis in a unilateral ureteral obstruction (UUO) mouse model and on fibrosis and apoptosis in HK-2 cells after 24 and 48 h induction by TGF-β. A miRNA microarray analysis was used to compare miRNA expression profiles in MSC EVs and EPO-EVs. The miRNA expression profile showed that the expression of 212 miRNAs in EPO-EVs changed significantly (fold-change ≥ 1.5), including miR-299, miR-499, miR-302, and miRNA-200. A total of 70.28% of those miRNA changes were upregulation. Although the authors did not perform knockout validation on upregulated miRNAs, they did indirectly confirm that miRNA alteration in pretreated EVs may underlie enhanced AKI.

Antifibrosis in UUO

In addition to global miRNA expression profiles, the protective effect of MSC EV-derived miRNAs on AKI has also been studied for specific miRNAs. In in vitro experiments, TGF-β was used to induce epithelial-mesenchymal transition (EMT) in HK-2 cells. Bone marrow-derived MSC EVs from young and aged rats were given to HK-2. The results showed that the inhibitory effect of MSC EVs from aged rats on EMT was significantly reduced. By comparison, they found that the expression of miR-344a, miR-133b-3p, miR-294, miR-423-3p, and miR-872-3p in MSC EVs of aged rats was significantly lower than that in young rats; the serum miRNA levels showed the same patterns. Direct intervention of TGF-β-induced HK-2 cells with the 4 miRNAs showed that miR-133b-3p and miR-294 significantly inhibited EMT in HK-2 cells [19]. miR-133b also played a protective role in other organs with effects such as inhibition of myocardial remodeling [20], improved cerebral ischemia [21], and reduced spinal cord injury [22]. However, some studies have found that knockdown of miR-133b and miR-199b alleviates diabetic nephropathy, renal fibrosis, and TGF-β1-induced EMT through sirtuin 1 (SIRT1) [23]. Therefore, the function of miR-133 in kidney fibrosis needs to be further investigated.

In 2000, a study in Nature first reported the regulatory effect of let-7 miRNAs on nematode development [24]. Let-7 is highly conserved among multiple species [25] and may play a protective role in kidney fibrosis. JASN published an article in 2013 reporting that lipoxin-induced let-7c can reduce renal fibrosis through inhibition of TGFβR1, demonstrating for the first time the important role of let-7 in kidney fibrosis [26]. Wang et al. conducted a series of studies on the relationship between let-7 and kidney injury. In diabetic and nondiabetic renal fibrosis models, let-7b expression decreases as TGFβR1 increases. Let-7b can directly inhibit the expression of TGF-β1 receptor 1 (TGF-β1), reduce extracellular matrix proteins, decrease the activity of TGF-β1, and reduce the profibrotic effect of TGF-β1 on normal rat kidney epithelial cells. NRK52E through binding targeted genes [27]. Subsequently, they used gene editing technology to overexpress let-7c in human bone marrow which resulted in a significant increase in let-7c in MSC EVs. Fluorescence microscopy was used to observe the transport of EVs to NRK52E cells, revealing increased expression of let-7c in NRK52E cells. After GW4869 treatment to inhibit EV production, the aforementioned changes and inhibitory effects on fibrosis all weakened. MSCs overexpressing let-7c also exert a better therapeutic effect on UUO [28].

Anti-inflammatory and anti-apoptosis effects in ischemia-reperfusion injury (IRI)

Inflammation plays an important role in the pathophysiology of AKI. Various specific inflammatory cells and pro-inflammatory cytokines/chemokines increase in the kidney during early AKI caused by ischemia reperfusion [29]. The chemokine C-X3-C motif chemokine ligand 1 (CX3CL1), a macrophage chemokine, is mainly expressed in endothelial cells. Inhibition of CX3CR1 can reduce macrophages in injured kidneys and has therapeutic effects on AKI [30]. Therefore, CX3CL1 is an important anti-inflammatory target for the treatment of renal IRI. Wharton’s jelly is another important source of MSCs other than the bone marrow. When Zou administered human Wharton’s jelly MSC (hWJMSC) EVs to IRI rats, apoptosis was alleviated, proliferation was enhanced, and the inflammatory response was alleviated at 48 h in the kidney. Additionally, hWJMSC EVs inhibited CX3CL1 expression and reduced the number of CD68+ macrophages in the kidney. By searching for miRNAs predicted to target CX3CL1 in the TargetScan database, multiple miRNAs (miR-15a, miR-15b, miR-16, miR-195, miR-424, and
miR-497) that might be involved in the regulation were discovered. Finally, RT-PCR analysis showed that hWJMSC EVs contained higher levels of miR-15a, miR-15b, and miR-16. However, the author did not further validate these 3 miRNAs. NLR family-pyrin domain containing 3 (NLRP3) inflammasomes promote inflammatory cytokine production during kidney injury and are highly expressed after renal tubular injury [31]. miRNA-233 can regulate NLRP3 expression [32]. The protective effect of MSC EVs on the heart is also associated with miRNA-233 [33]. Hypoxia preconditioning significantly increased miRNA-233 levels in MSCs and inhibited hypoxia/reoxygenation (H/R)-induced renal tubular cell apoptosis. A dual luciferase assay showed that miR-223 directly inhibited NLRP3 expression and activated Notch1. After knockdown of miRNA-233 in MSCs, H/R-induced renal tubular apoptosis was significantly increased. In vivo experiments also showed that the protective effect of MSCs on renal ischemia injury significantly decreased after miRNA-233 knockdown [34]. Although this study only used MSC therapy without EVs, miRNA-233 in EVs may be one of the mechanisms by which MSCs exert their therapeutic effect. The miRNAs in exosomes secreted from human bone marrow MSC EVs consisted of many miRNAs and miR-199a-3p was the most abundant. It has been found that exosomes loaded with a high dose of miR-199a could prevent cardiomyocyte apoptosis [35]. MSC exosome treatment could also increase the expression level of miR-199a-3p in renal cells and prevent IRI injury of the kidney. According to the prediction of target gene, Sema3A, a member of class 3 semaphorins, mediated the effect of miR-199a-3p. The activation of Sema3A could suppress the protein kinase B (AKT) and extra-cellular signal-regulated kinase (ERK) pathways, which are related to cell survival [36].

In addition to inflammatory responses, studies have shown that mitochondrial dynamics also contribute to pathological changes after renal IRI [37]. Under IRI-induced stress, mitochondria dynamics shift to the dividing state, eventually leading to mitochondrial disruption and apoptosis [38]. Dynamin-related protein 1 (Drp1) is a key factor affecting mitochondrial division. Inhibition of Drp1 can block mitochondrial rupture and protect renal ischemia or cisplatin-induced acute injury [39]. miRNA-30 regulates mitochondrial division in cardiomyocytes through Drp1 [40]. Additionally, miR-30 also imparts renal protection through inhibition of apoptosis [41] and fibrosis [42]. However, the relationship with mitochondria dynamics has not been studied extensively in the kidney. Gu et al. observed injury and mitochondrial morphology in IRI rats treated with hWJMSC EVs and found that the expression of miRNA-30 in the kidneys of the treatment group rats increased, DRP1 expression decreased, mitochondria returned to a normal state, and apoptosis was reduced. After antagonimR was used to reduce miRNA-30 expression in MSC EVs, the therapeutic effect of EVs was significantly reduced [43]. These results suggest that miRNA-30 in EVs protect mitochondrial morphology and apoptosis in the kidney by regulating DRP1.

**Therapeutic effect of miRNAs on AKI in progenitor cell EVs**

In 1997, Asahara isolated circulating endothelial progenitor cells (EPCs). This CD34+ cell type contributes to angiogenesis [44]. EPCs circulate in the peripheral blood and can home in on injured tissues and organs, release angiogenic factors and EVs, stimulate local endothelium, and differentiate into mature endothelial cells that incorporate into injured tissue to replace or support the existing endothelium, form new blood vessels, and promote vascular repair and regeneration [45]. Previous studies also confirmed that EPCs have therapeutic effects on AKI [46]. Dicer is an endonuclease that belongs to the RNase III family and specifically recognizes double-stranded RNA. Dicer digests pre-miRNA to form mature miRNA. Cantalupi et al. found that exogenously administered EPC EVs colonize glomeruli and renal tubules after renal IRI. Dicer knockout eliminates miRNAs in EPCs, which reduces the protective effect of EVs on renal IRI. Finally, it was found that miR126 and miR-296 might mediate EPC EV actions through promoting cell proliferation and reducing apoptosis and inflammatory cell infiltration [47]. Previous studies demonstrated that miRNA-126 regulates the PI3K pathway, regulates cell regeneration, and plays a protective role in the kidney [14]. Studies have shown that miR-296 is highly expressed in aged F344 rats, and pathway analysis revealed that it may be associated with inflammation in kidneys of elderly individuals [48]. However, this study was not verified. Additionally, the miRNA expression profile analysis of F344 rats was not representative. AKI is a type of acute injury, while kidney damage in elderly individuals may result from chronic processes. miR-296 may play different roles at different stages. In the future, miR-296 should be studied further by establishing an acute and chronic kidney model for the elderly.

Endothelial colony-forming cells (ECPCs) are one type of EPC [49]. A series of studies by Burger and Viñas on ECPCs also confirmed that in hypoxic/reoxygenation (H/R) human umbilical vein endothelial cells and an IRI rat model, ECPC EVs alleviate renal cell oxidative stress-induced injury and cell apoptosis [50]. Subsequently, microRNA-486-5p in ECPC EVs were found to inhibit epithelial cell apoptosis by regulating the PTEN/Akt pathway [51]. miRNAs in EVs can play a protective role in the AKI process, while inhibiting miRNAs in EVs may reduce renal protection through inhibition of apoptosis [40]. Additionally, miR-30 also imparts renal protection through inhibition of apoptosis [41] and fibrosis [42]. However, the relationship with mitochondria dynamics has not been studied extensively in the kidney. Gu et al. observed injury and mitochondrial morphology in IRI rats treated with hWJMSC EVs and found that the expression of miRNA-30 in the kidneys of the treatment group rats increased, DRP1 expression decreased, mitochondria returned to a normal state, and apoptosis was reduced. After antagonimR was used to reduce miRNA-30 expression in MSC EVs, the therapeutic effect of EVs was significantly reduced [43]. These results suggest that miRNA-30 in EVs protect mitochondrial morphology and apoptosis in the kidney by regulating DRP1.
renal tissue damage. Pang et al. isolated CD34+/CD105−renal artery-derived vascular proliferative cells (RAPCs) from the renal artery of patients during radical nephrectomy. These cells showed EPC-like characteristics as they integrated into glomerular capillaries to increase the capillary density in the kidneys of ischemic rats. After inhibiting the expression of miRNA-218 in RAPCs, the RAPC EVs had enhanced promotion of endothelial cell migration. This may be because the inhibition increased roundabout protein (Robo-1) mRNA in EVs, and Robo-1 further migrated to the kidney during treatment to promote endothelial migration [52]. Robo-1 can contribute to the regulation of angiogenesis and endothelial cell migration.

Other stem cell EVs, such as stem cells isolated from urine, liver-derived stem cells, and glomerular stem cells, also play protective roles in acute and chronic kidney injury [53]. However, the role of miRNAs in EVs secreted by these stem cells has not yet been studied in depth.

Conclusions
In summary, EVs secreted by stem cells play important roles in the injury and repair of AKI through miRNAs, mainly through anti-fibrotic, anti-inflammatory, and anti-apoptotic functions in UUO and ischemic injury. They can also promote tissue repair and regeneration. In the future, miRNAs may not only be used as biomarkers for AKI injury but also as markers of stem cell treatment efficacy. However, to date, there are few studies on which miRNAs and associated target genes mediate the therapeutic effect of stem cell EVs on AKI. In addition to the studies covered in this review, other miRNAs that play a role remain to be determined. The main sources of EVs are currently concentrated in MSCs and EPCs, and the protective effect of other stem cell-derived miRNAs on AKI needs to be further clarified. miRNAs may play different roles during different stages of the physiology and pathology of the kidney. In summary, miRNA studies on EVs in stem cells provide important reference for clinical practice and provide new ideas for finding more effective and direct treatment strategies and therapeutic targets for acute and chronic kidney diseases.

Abbreviations
AKI: Acute kidney injury; BCL-2: B-cell lymphoma 2; CKD: Chronic kidney disease; CX3CL1: C-X3-C motif chemokine ligand 1; Drp1: Dynamin-related protein 1; EPCs: Endothelial colony-forming cells; EPO: Erythropoietin; EVs: Extracellular vesicles; Foxo3: Forkhead box O3; H/R: Hypoxia/reoxygenation; HGF: Hepatocyte growth factor; HIF: Hypoxia-inducible factor; HO-1: Heme oxygenase; HIV/MSC: Human Wharton’s jelly MSC; miRNA: MicroRNA; MSCs: Mesenchymal stem cells; NLRP3: NLR family pyrin domain containing 3; PI3K: Phosphoinositide 3-kinases; PTEN: Phosphatase and tensin homolog; RAPCs: Renal artery-derived vascular proliferative cells; Robo-1: Roundabout protein; TFAM: Mitochondrial transcription factor A; TGFBR1: Transforming growth factor-β receptor type 1; UUO: Unilateral ureter obstruction; VEGF: Vascular endothelial growth factor

Acknowledgements
The authors would like to thank the laboratory members for their contributions.

Authors’ contributions
SW contributed to the conception of this manuscript and drafted the manuscript. SW and GC revised the manuscript. All authors read and approved the final manuscript.

Funding
This work is supported by the National Key R&D Program of China (2018YFA0108803) and the Science and Technology Project of Beijing (D18110000118004).

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Published online: 03 September 2019

References
1. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21:R125–34.
2. Breakfield XO, Frederickson RM, Simpson RJ. Gercules: microvesicle “cookies” for transient information transfer between cells. Molecular Therapy of the Am Soc Gene Therapy. 2011;19:574–6.
3. Liu B, Liu L, Trykin A, Goodall GJ, Cairns MJ, Li J. Discovering functional microRNA-mRNA regulatory modules in heterogeneous data. Adv Exp Med Biol. 2013;774:267–90.
4. Collino F, Bruno S, Incamato D, Dettori D, Nei F, Provero P, Pomatto M, Oliviero S, Tetta C, Quiesenbery PJ, Camussi G. AKI recovery induced by mesenchymal stromal cell-derived extracellular vesicles carrying miRNAs. J Am Soc Nephrol. 2015;26:2349–60.
5. Giuseppe T, Rosaria T, Gabriella S, Fabiana G. Extracellular membrane vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol. 2014;306:621–33.
6. J. Ratajczak, ., K. Miekus, ., M. Kucia, ., J. Zhang, ., R. Reca, ., P. Dvorak, ., M.Z. Ratajczak. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia. 2006; 20: 847–856.
7. Shuta I, Cantley LG. Epithelial-mesenchymal-epithelial cycling in kidney repair. Curr Opin Nephrol Hypertens. 2008;17:379.
8. Camussi G, Deregibus MC, Tetta C. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information. Curr Opin Nephrol Hypertens. 2010;19:7–12.
9. Tsui K, Kitamura S, Wada J. Secretomes from mesenchymal stem cells against acute kidney injury: possible heterogeneity. Stem Cells Int. 2018; 2018:1–14.
10. Valadi H, Ekstrom K, Bossios A, Sjostrands M, Lee JJ, Lotvall JO. Exosomes and microvesicles: extracellular vesicles as a mechanism of cell-to-cell communication: advantages and disadvantages. Am J Physiol Cell Physiol. 2011;306:621–33.
11. Alex Y, Farber EL, Ana Lia R, Desiree T, Roman D, Akhmedov NB, Farber DB. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One. 2009;4:e4722.
12. Gatti S, Bruno S, Deregibus MC, Sordi A, Cantaluppi V, Tetta C, Camussi G. Microvesicles derived from human adult mesenchymal stem cells protect against ischemia/reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant. 2011;26:1474–83.
13. Qingqing W, Qing-Sheng M, Zheng D. The regulation and function of microRNAs in kidney diseases. IUBMB Life. 2013;65:602–10.
14. Liu Z, Wang S, Mi QS, Dong Z. MicroRNAs in pathogenesis of acute kidney injury. Nephron. 2016;134:149–53.
15. Guo Y, Ni J, Chen S, Bae M, Lin J, Ding G, Zhang Y, Sun P, Jia Z, Huang S, Yang L, Zhang A. MicroRNA-709 mediates acute tubular injury through effects on mitochondrial function. J Am Soc Nephrol. 2018;29:4949–61.

16. de Almeida DC, Basí J, Azevedo H, Anderson L, Oringassa C, Cenedese MA, de Andrade-Oliveira V, Felizardo RA, da Silva RC, Hiyane MI, Semed P, Dos Reis MA, Moreira-Filho GA, Verjovski-Almeida S, Pacheco-Silva A, Camara NO. A regulatory miRNA-mRNA network is associated with tissue repair induced by mesenchymal stromal cells in acute kidney injury. Front Immunol. 2016;7:645.

17. Kouremanbas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Ann Rev Physiol. 2015;77:13–27.

18. Lindoso RS, Collino F, Bruno S, Araújo DS, Sant’Anna JF, Tetta C, Provero P, Quevenby PJ, Veyra A, Ennicker-Lamas M, Camussi G. Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury. Stem Cells Dev. 2014;23:1809–19.

19. Wang Y, Fu B, Sun X, Li D, Huang Q, Zhao W, Chen X. Differentially expressed microRNAs in bone marrow mesenchymal stem cell-derived microvesicles in young and older rats and their effect on tumor growth factor-beta 1-mediated epithelial-mesenchymal transition in H2O2 cells. Stem Cell Res Ther. 2015;6:185.

20. Ning L, Heng Z, Qzhou T. mir-133: a suppressor of cardiac remodeling? Front Pharmacol. 2018;9:7093.

21. Huang B, Jiang XC, Zhang TY, Hu YL, Tabata Y, Chen Z, Pluchino S, Gao JQ. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Ann Rev Physiol. 2015;77:13–27.

22. Zhou J, Zou Y, Hu G, Lin C, Guo Y, Gao K, Wu M. Facilitating colorectal cancer cell metastasis by targeting bound of long non-coding RNA ENSG00000231881 with miR-133b via VEGFC signaling pathway. Biochem. Biophys. Res. Commun. 2019;509:1–7.

23. Sun Z, Ma Y, Chen F, Wang S, Chen B, Shi J. miR-133b and miR-199b knockdown attenuate TGFB-induced epithelial to mesenchymal transition and renal fibrosis by targeting SIRT1 in diabetic nephropathy. Eur J. Pharm. 2018;837:96–104.

24. B.E. Reinhart, F.J. Slack, M. Basso, A.E. Pasquinelli, J.C. Bettinger, A.E. Roush, H.R. Horvitz, G.R. Ruvkun. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403: 901–906.

26. Brennan EP, Nolan KA, Emma BR, Gough OS, Mcevoy CM, Docherty NG, Dummeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol. 2005;39:733–42.

30. GalešićJubanović D. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol. 2008;294:F254.

32. Akoucha V, Justin C, Seamone ME, Wenjie W, Rick C, Simon H, Yan L, Clark SA, Jurg T, Kiril T. The NLPR3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21:1732–44.

34. Yuan X, Wang X, Chen C, Zhou J, Han M. Bone mesenchymal stem cells ameliorate ischemia/reperfusion-induced damage in renal epithelial cells via microRNA-223. Stem Cell Res Ther. 2017;8:146.

35. Ferguson SW, Wang J, Lee CJ, Liu M, Neelamegham S, Canty JM, Nguyen J. The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Scientific Reports. 2018;8:1419.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.